Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
Krop I, Welslau M, Samant M, Miles D, Lu M, Huober J, Guardino E, Blackwell K, Lin N, Diéras V. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 2014; 26:113-119.
29.10.2014
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
29.10.2014
Ann Oncol 2014; 26:113-119
Krop I E, Welslau M, Samant M, Miles D, Lu M, Huober Jens, Guardino E, Blackwell K, Lin N U, Diéras V
Weiter
